By: Erin Hutzell. Background: Breast Cancer Second leading cause of death due to cancer among women in 2007 1 in 3 women diagnosed with cancer is diagnosed.

Slides:



Advertisements
Similar presentations
© 2013 North American Menopause Society. Menopause. 2013;20(9): Key points from the 2013 Position Statement of The North American Menopause Society.
Advertisements

Breast cancer chemoprevention in the high-risk patient
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Study of Tamoxifen and Raloxifene (STAR): Initial Findings from the NSABP P-2 Breast Cancer Prevention Study D.L. Wickerham, J.P. Costantino, V. Vogel,
CONTROVERSIES IN ADJUVANT ENDOCRINE THERAPY AROMATASE INHIBITORS
Systemic therapy for Metastatic Breast Cancer Jo Anne Zujewski, MD National Cancer Institute May 2011.
Why can’t we prevent breast cancer? Actually, we can … The treatment can be worse than the disease – The preventative can be worse than the risk Topics.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Chapter 61 Estrogens and Progestins: Basic Pharmacology and Noncontraceptive Applications 1.
Cardiovascular Disease in Women Module VI: Update on Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators (SERMs)
Jack Cuzick, Ph.D. Wolfson Institute of Preventive Medicine St Bartholomew’s Medical School London, United Kingdom Implementation Issues for Chemoprevention.
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
1 SERM’s IES Winter Conference Iris Vered, Sheba Medical Center Tel Hashomer.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
GYN ONCOLOGY OBesity Project. “Obesity is linked as a cause of 20% of cancer deaths in women.”
Hormonal Replacement Therapy for postmenopausal females: To give or not to give? Amna B. Buttar, MD, MS Assistant Professor of Clinical Medicine Indiana.
Menopause: The Journal of The North American Menopause Society
The P-4 NSABP Trial: NCAB Subcommittee Recommendations Bruce A. Chabner, MD June 16, 2007.
1 Study of Tamoxifen and Raloxifene STAR Larry Wickerham, MD NSABP STAR Project Officer.
Prevention and Early Detection of Breast Cancer: Weighing the Risks and Benefits Kathy J. Helzlsouer, M.D., M.H.S. Prevention and Research Center, Women’s.
Medication Options H ealthPLACE/HOPE Program COPYRIGHT © 2002 Highmark Inc. All Rights Reserved. These materials may not be copied or otherwise reproduced.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
These slides were released by the speaker for internal use by Novartis
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
FDA Presentation ODAC Meeting July NDA Applicant: Eli Lilly Evista ® (Raloxifene Hydrochloride)
Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,
1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.
Food and Drug Administration Regulatory Implications of The WHI Study Eric Colman, MD Center for Drug Evaluation and Research Division of Metabolic and.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Breast Cancer Prevention Art or Science? Kristi McIntyre M.D. Texas Oncology 2005.
A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.
MENAPOUSE. Natural Surgical premature RETROSPECTIVE Cessation of menstruation for 12 months In the absence of other physiological or psychological.
STAR. 2 NSABP P-1 Trial Results: Age > 50 Category TamoxifenPlacebo ARD RR(95% CI) n 4010 IR n 4008 IR Breast Cancer Invasive Invasive Non-invasive Non-invasive
Anastrozole (‘Arimidex’): a new standard of care?
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
A RAY OF HOPE: TAMOXIFEN POWERPOINT PRESENTATION BY NEIL RAKHOLIA
Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.
1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.
Chemoprevention of cancer Dr Manal Kahwaji Cancer fighting day Feb 2, 2016.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Practical Issues in Counseling Healthy Women About.
Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
Breast Cancer Mechanisms 1. 2 Her
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
HORMONE REPLACEMENT THERAPY (HRT) Evidence-based Guidelines Dr Mahdy El- Mazzahy Damietta general Hospital 7 th International Annual Congress “Alexandria”
© Copyright Annals of Internal Medicine, 2016 Ann Int Med. 164 (6): ITC6-1. In the Clinic Breast Cancer Screening and Prevention.
Date of download: 6/27/2016 From: Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer Ann Intern Med.
Date of download: 7/18/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Chart for identifying appropriate candidates for postmenopausal.
CCO Independent Conference Coverage
AROMATASE INHIBITORS.
SERMs Dr Sarvesh Singh Associate Professor
San Antonio Breast Cancer Symposium, December 6-10, 2016
Breast Cancer Updates Risks, Genetics, DCIS
Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*
JOURNAL OF CLINICAL ONCOLOGY 25:
Mostafa AL Turk Tatiana Hawat
SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,
Breast Health Katherine B. Lee, MD, FACP April 26, 2018.
Chapter 61 Estrogens and Progestins: Basic Pharmacology and Noncontraceptive Applications 1.
Drugs for Bone and Joint Disorders
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
Bergh J et al. SABCS 2009;Abstract 23.
Treatment of HR+ Breast Cancer: A Clinical Update
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
Volume 381, Issue 9880, Pages (May 2013)
Presentation transcript:

By: Erin Hutzell

Background: Breast Cancer Second leading cause of death due to cancer among women in in 3 women diagnosed with cancer is diagnosed with breast cancer Risk Factors Environmental Genetic

Background: Breast Cancer Invasive VS. Noninvasive Estrogen Receptor (ER) positive VS. Estrogen Receptor negative Mechanism causing breast cancer

Background: Chemoprevention and Drugs Chemoprevention What is it? Tamoxifen Selective Estrogen Receptor Modulator (SERM) Raloxifene SERM Exemestane Aromatase Inhibitor (AI)

Questions How effective is each drug in preventing breast cancer? What are the side-effects of each drug treatment? Which drug is the best possible chemopreventative measure for breast cancer?

Tamoxifen * Modified from Grese et al 1997

Tamoxifen NSABP P-1 Study by Fisher et al (1998) Subject Criteria 60 years years with predicted breast cancer risk History of lobular carcinoma in situ or atypical hyperplasia Methods Control group Tamoxifen group

Tamoxifen Supported By: IBIS-I Study (Cuzick et al 2002) Meta-analysis by Cuzick et al Not Supported By: Royal Marsden (Powles et al 1998) Italian Tamoxifen Prevention Study (Veronesi et al 1998) Top: Fisher et al Bottom: Fisher et al * Kramer et al. 2004

Tamoxifen NSABP P-1 (Fisher et al 1998 and 2005) Osteoporotic Fractures: REDUCED Invasive Endometrial Cancer: RISK INCREASED Supported by IBIS-I (Cuzick et al 2002) and Royal Marsden (Powles et al 1998) Thromboembolic Events: RISK INCREASED Supported by IBIS-I, Royal Marsden, and Italian Tamoxifen Prevention Study (Veronesi et al 1998) Conclusion: Tamoxifen is an effective drug but has adverse side-effects * Kramer et al. 2004

Raloxifene * Structures of Tamoxifen and Raloxifene highlighting structural differences from Grese et al 1997

Raloxifene Continuing Outcomes Relevant to Evista (CORE) trial by Martino et al (2004) Subject Criteria Postmenopausal women with osteoporosis from an earlier trial (MORE trial) Methods Raloxifene group Placebo group

Raloxifene * Martino et al * Table modified from Nelson et al that compares the effectiveness of Tamoxifen and Raloxifene

Raloxifene * Table of the combined results of the primary prevention trials of Raloxifene and Tamoxifen demonstrating side-effects (modified from Nelson et al. 2013)

Exemestane ary/summary.cgi?cid=60198

Exemestane Mammary Prevention.3 (MAP3) Trial by Goss et al (2011) Subject Criteria Postmenopausal Women At least one risk factor Methods Exemestane Placebo

Exemestane Conclusion: Exemestane is a more effective chemopreventative than Tamoxifen Supported by: Intergroup Exemestane Study by Bliss et al (2012) Exemestane produced better disease-free survival Drug RegimenRisk Reduction Tamoxifen (20 mg daily for 5 years) 43% Exemestane (25 mg daily for 3 years) 65% Comparison of the risk reductions for Tamoxifen and Exemestane Table modified from Zhang et al * Goss et al 2011

Exemestane Drug Regimen Effect on Bone Common Adverse Effects Serious But Rare Adverse Events Indicated Population Exemestane (25 mg daily for 3 years) UnfavorableHot flashes, nausea, diarrhea, fatigue, insomnia, joint pain, arthralgia Not identifiedNot FDA approved; postmenopausal women only Tamoxifen (20 mg daily for 5 years) NeutralHot flashes, vaginal discharge, bleeding, altered menses, fluid retention, nausea, vomiting, weight loss, athralgia Endometrial cancer, thromboembolism, stroke, heart attack, cataracts FDA-approved for premenopausal and postmenopausal women with a 5 year risk of ≥1.66% Comparison of the side-effects of Tamoxifen, Raloxifene, and Exemestane Table modified from Zhang et al. 2012

Conclusion DrugRisk ReductionSide-Effects TamoxifenLow (43%)Severe Exemestane High (65%)Few/No Severe Exemestane has the potential to be the best possible chemopreventative measure for breast cancer Future: Research Exemestane Explore Medication Combinations Demographics of Patients

Bibliography